Genetic Technologies Stock

Genetic Technologies EBIT

The EBIT of Genetic Technologies (GTG.AX) as of Aug 10, 2026 is -10.61 M AUD. In the previous year, EBIT was -10.19 M AUD — a change of 4.12% (lower).

EBIT

-10.61 MAUD

YoY

4.12%

Last updated:

In 2026, Genetic Technologies's EBIT was -10.61 M AUD, a 4.12% increase from the -10.19 M AUD EBIT recorded in the previous year.

The Genetic Technologies EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M AUD)
Date
EBIT (M AUD)
Jan 1, 2017
-7.74 base
Jan 1, 2018
-6.11 base
Jan 1, 2019
-6.00 base
Jan 1, 2020
-6.54 base
Jan 1, 2021
-7.69 base
Jan 1, 2022
-7.57 base
Jan 1, 2023
-10.19 base
Jan 1, 2024
-10.61 base
YEAREBIT (M AUD)
2024 -10.61
2023 -10.19
2022 -7.57
2021 -7.69
2020 -6.54
2019 -6.00
2018 -6.11
2017 -7.74
2016 -8.50
2015 -9.54
2014 -9.81
2013 -9.14
2012 -11.01
2011 1.05
2010 -7.47
2009 -7.50
2008 -2.75
2007 -2.62
2006 -7.70
2005 -9.45
Access this data via the Eulerpool API

Genetic Technologies Revenue

Genetic Technologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
518,500.00 AUD
-7.74 M AUD
-8.40 M AUD
Jan 1, 2018
189,300.00 AUD
-6.11 M AUD
-5.46 M AUD
Jan 1, 2019
25,400.00 AUD
-6.00 M AUD
-6.43 M AUD
Jan 1, 2020
9,900.00 AUD
-6.54 M AUD
-6.29 M AUD
Jan 1, 2021
120,600.00 AUD
-7.69 M AUD
-7.08 M AUD
Jan 1, 2022
6.79 M AUD
-7.57 M AUD
-7.13 M AUD
Jan 1, 2023
8.69 M AUD
-10.19 M AUD
-11.75 M AUD
Jan 1, 2024
7.66 M AUD
-10.61 M AUD
-12.02 M AUD

Genetic Technologies Margins

Genetic Technologies stock margins

The Genetic Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genetic Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genetic Technologies.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
5.03 %
-1,493.19 %
-1,620.79 %
Jan 1, 2018
-58.53 %
-3,225.41 %
-2,886.37 %
Jan 1, 2019
-987.40 %
-23,614.57 %
-25,297.64 %
Jan 1, 2020
-925.25 %
-66,014.14 %
-63,583.84 %
Jan 1, 2021
-41.38 %
-6,372.89 %
-5,868.66 %
Jan 1, 2022
55.65 %
-111.41 %
-104.95 %
Jan 1, 2023
50.09 %
-117.37 %
-135.28 %
Jan 1, 2024
50.94 %
-138.49 %
-156.78 %

Genetic Technologies Stock analysis

What does Genetic Technologies do? Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Genetic Technologies's EBIT

Genetic Technologies's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Genetic Technologies's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Genetic Technologies's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Genetic Technologies’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Genetic Technologies stock

EBIT of Genetic Technologies is -10.61 M AUD in 2026.

EBIT of Genetic Technologies changed from -10.19 M AUD to -10.61 M AUD, representing a 4.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Genetic Technologies since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Genetic Technologies historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Genetic Technologies

All Key Metrics — Genetic Technologies